Bausch + Lomb Resumes enVista IOL Sales After Voluntary Recall Resolution
Overview
Bausch + Lomb has identified the cause of the recent voluntary recall of enVista intraocular lenses (IOLs) as raw material issues from a new vendor. Following a thorough investigation and implementation of enhanced quality controls, the company is returning these IOLs to the market with confidence in their safety.
Background
The enVista IOL platform experienced a voluntary recall due to reported cases of toxic anterior segment syndrome (TASS) linked to certain lens lots. An advisory group of nearly 30 leading cataract surgeons and a globally recognized TASS expert collaborated with Bausch + Lomb to investigate the issue. The investigation pinpointed raw materials from a different vendor as the root cause. Patient safety was prioritized throughout the process, leading to the recall and subsequent corrective actions.
Data Highlights
Bausch + Lomb identified a tight correlation between specific lots of enVista IOLs and reported TASS cases. Enhanced inspection protocols and stricter vendor standards for monomer preparation have been implemented. The company plans to resume full production and market supply in the United States imminently, with international market reentry pending regulatory approval.
Key Findings
- The recall was voluntarily initiated due to patient safety concerns related to TASS events.
- Investigation revealed raw material issues from a new vendor as the cause of the problem.
- Nearly 30 top cataract surgeons and a TASS expert were involved in the thorough investigation.
- Enhanced inspection protocols and vendor standards have been established to prevent recurrence.
- Full production of enVista IOLs has resumed with plans for phased market reentry.
Clinical Implications
Clinicians can be reassured that enVista IOLs have undergone rigorous investigation and quality improvements before returning to market. Awareness of the recall and its resolution supports informed decision-making when selecting IOLs for cataract surgery. Continued vigilance for TASS remains important, but current data support the safety profile of enVista lenses.
Conclusion
Bausch + Lomb’s comprehensive response to the enVista IOL recall underscores its commitment to patient safety and product quality. With corrective measures in place, the enVista platform is now reintroduced to the market with restored confidence.
References
- Bausch + Lomb Press Release 2024 -- enVista IOL Recall and Market Return
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.